Literature DB >> 31073350

Effective steroid therapy in an elderly patient with cardiac sarcoidosis and severe left ventricular dysfunction.

Kyoko Odawara1, Takahiro Inoue1, Yoshitaka Hirooka1,2.   

Abstract

A 75-year-old woman with no significant medical history was admitted to our hospital with congestive heart failure. Echocardiography revealed left ventricle (LV) systolic dysfunction [LV ejection fraction (LVEF) 18%] and diffuse LV hypokinesis mimicking dilated cardiomyopathy. Her brain natriuretic peptide (BNP) level was elevated (1214.3 pg/mL). Standard medications for heart failure failed to ameliorate her cardiac failure symptoms. Echocardiography on admission revealed thickening of the basal interventricular septum without morphological changes. Cardiac magnetic resonance imaging showed late enhancement in the epicardial side dominance of the LV at the late phase. Lysozyme and soluble interleukin 2 receptor levels were elevated. No abnormalities were found in the lungs, eyes, or skin, and she was diagnosed with cardiac sarcoidosis. At 23 days after beginning treatment, the patient received oral steroid therapy (prednisolone 30 mg/day) along with standard heart failure medications. The dose was tapered by 5 mg at 4-week intervals and then maintained at 10 mg per day. At 17 days after initiating steroid therapy, her BNP value decreased and remained at a low level. Echocardiography showed improvement of the LV dimensions and LVEF. In patients with severe LV dysfunction diagnosed with cardiac sarcoidosis, we propose that careful steroid therapy be considered, even for elderly patients. <Learning objective: Although little is known about cardiac sarcoidosis, it should be considered even in elderly patients with refractory arrhythmias or intractable heart failure. Considering cardiac sarcoidosis as an etiology as well as early initiation of steroid therapy in patients exhibiting severe left ventricular dysfunction may be beneficial.>.

Entities:  

Keywords:  Cardiac sarcoidosis; Heart failure; Left ventricular dysfunction; Steroid therapy

Year:  2019        PMID: 31073350      PMCID: PMC6495045          DOI: 10.1016/j.jccase.2018.12.019

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

1.  Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis.

Authors:  Chiung-Zuan Chiu; Satoshi Nakatani; Guican Zhang; Teruo Tachibana; Fumio Ohmori; Masakazu Yamagishi; Masafumi Kitakaze; Hitonobu Tomoike; Kunio Miyatake
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

2.  Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement.

Authors:  Yoichi Takaya; Kengo Fukushima Kusano; Kazufumi Nakamura; Mitsumasa Kaji; Takayoshi Shinya; Susumu Kanazawa; Hiroshi Ito
Journal:  Int J Cardiol       Date:  2014-07-12       Impact factor: 4.164

Review 3.  Corticosteroid therapy for cardiac sarcoidosis: a systematic review.

Authors:  Mouhannad M Sadek; Derek Yung; David H Birnie; Rob S Beanlands; Pablo B Nery
Journal:  Can J Cardiol       Date:  2013-04-24       Impact factor: 5.223

4.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.

Authors:  Riina Kandolin; Jukka Lehtonen; Juhani Airaksinen; Tapani Vihinen; Heikki Miettinen; Kari Ylitalo; Kari Kaikkonen; Suvi Tuohinen; Petri Haataja; Tuomas Kerola; Jorma Kokkonen; Markus Pelkonen; Päivi Pietilä-Effati; Seppo Utrianen; Markku Kupari
Journal:  Circulation       Date:  2014-12-19       Impact factor: 29.690

5.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.

Authors:  Y Yazaki; M Isobe; M Hiroe; S Morimoto; S Hiramitsu; T Nakano; T Izumi; M Sekiguchi
Journal:  Am J Cardiol       Date:  2001-11-01       Impact factor: 2.778

6.  Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan.

Authors:  Michiru Sawahata; Yukihiko Sugiyama; Yosikazu Nakamura; Masayuki Nakayama; Naoko Mato; Hideaki Yamasawa; Masashi Bando
Journal:  Respir Med       Date:  2015-01-03       Impact factor: 3.415

7.  Untreated cardiac sarcoidosis with active inflammation: Severe left ventricular dysfunction and ventricular wall thinning in three years.

Authors:  Ryota Kakizaki; Toshimi Koitabashi; Yoshiyasu Minami; Takeru Nabeta; Toyoji Kaida; Shunsuke Ishii; Emi Maekawa; Takayuki Inomata; Junya Ako
Journal:  J Cardiol Cases       Date:  2017-08-05

Review 8.  Cardiac Sarcoidosis.

Authors:  David H Birnie; Pablo B Nery; Andrew C Ha; Rob S B Beanlands
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

9.  Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan.

Authors:  K Iwai; T Tachibana; T Takemura; Y Matsui; M Kitaichi; Y Kawabata
Journal:  Acta Pathol Jpn       Date:  1993 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.